3711c9b4-a52b-4786-8bf8-5b6a59605c16
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.300
- INTERFERON_ALPHA_RESPONSE+0.300
- KRAS_SIGNALING_DN+0.300
- ANGIOGENESIS+0.200
- APICAL_SURFACE+0.200
- ESTROGEN_RESPONSE_EARLY+0.200
- ESTROGEN_RESPONSE_LATE+0.200
- INTERFERON_GAMMA_RESPONSE+0.200
- MYOGENESIS+0.200
- ADIPOGENESIS+0.100
Top 10 suppressed
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.500
- MITOTIC_SPINDLE-0.300
- MTORC1_SIGNALING-0.300
- NOTCH_SIGNALING-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- CHOLESTEROL_HOMEOSTASIS-0.200
- DNA_REPAIR-0.200
- HYPOXIA-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG585 | — | — | 0.696 |
| 2 | SRR2932812 | — | — | 0.689 |
| 3 | TCGA-97-A4M5-01A-11R-A24X-07 | — | cohortA1 | 0.687 |
| 4 | SRR614155 | GTEX | — | 0.670 |
| 5 | SRR598276 | GTEX | — | 0.664 |
| 6 | SRR1476186 | GTEX | — | 0.663 |
| 7 | MNG7 | — | — | 0.657 |
| 8 | BS_0BXY0F9N | EPN | Posterior Fossa EPN | 0.654 |
| 9 | BS_BPSTSCBJ | pilocytic astrocytoma | — | 0.653 |
| 10 | SRR1476279 | GTEX | — | 0.652 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |